BridgeBio cancelled its appearance nest week at a Guggenheim conference next week "because of a conflict," Guggenheim analyst Debjit Chattopadhyay told Bloomberg via email. BofA analyst Greg Harrison earlier today attributed the stock’s rally to reports continuing to circulate around takeover interest after BridgeBio canceled a conference presentation. Shares of BridgeBio in late Wednesday trading rose 16% to $17.51.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio likely worth $3B-$4B in takeover, says BofA
- BridgeBio Pharma call volume above normal and directionally bullish
- Here’s Why Investors Are Excited About BridgeBio (NASDAQ:BBIO) Stock
- BridgeBio attracting bigger companies’ takeover interest, Bloomberg says
- BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO
